Compare Lululemon Athletica Inc (LULU) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Lululemon Athletica Inc trades at $94.08 (market cap $10.44B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Lululemon Athletica Inc is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lululemon Athletica Inc for 106 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LULU | SYRE | |
|---|---|---|
Market Cap | $10.44B | $7.52B |
Volume | 2,759,135 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $108.92 |
52-Week Low | $91.88 | $22.18 |
Typical Hold Time | 106 Days | 0 Days |
Enterprise Value | $11.20B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon stock trades at $94.09, down 54% year-to-date and near its 52-week low. The technical picture is bearish with resistance at $96 and support at $93. Fundamentally, the company reported strong revenue of $10.59B in 2025 and a net income margin of 12.78%, but faces growth concerns. Recent news highlights a securities fraud investigation and competitive pressures in athletic apparel.
The outlook is cautious due to legal overhangs and weakening sentiment, though valuation ratios like a P/E of 7.76 appear attractive. Risks include governance turmoil and consumer shifts. Analyst consensus is a $97.67 price target with a mixed buy/hold rating split, suggesting potential recovery if execution improves.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
